The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice.

MLA

Muela, Zarzuela, Inés, et al. “The NLRP3 Inhibitor Dapansutrile Improves the Therapeutic Action of Lonafarnib on Progeroid Mice.” Aging Cell, vol. 23, no. 9, Sept. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1111/acel.14272.

APA

Muela, Z. I., Suarez, R. J. M., Boy, R. D., López, P. J., Sotelo, M. M., del Mar, N. M., Collado, I. G., Botubol, A. J. M., Sanz, A., & Cordero, M. D. (2024). The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice. Aging Cell, 23(9), 1–10. https://doi.org/10.1111/acel.14272

Chicago

Muela, Zarzuela, Inés, Rivero, Juan Miguel Suarez, Ruiz, Daniel Boy, Pérez, Juan López, Montoro, Marta Sotelo, Navarrete‐Alonso, Maria del Mar, Isidro G. Collado, Ares, José Manuel Botubol, Alberto Sanz, and Mario D. Cordero. 2024. “The NLRP3 Inhibitor Dapansutrile Improves the Therapeutic Action of Lonafarnib on Progeroid Mice.” Aging Cell 23 (9): 1–10. doi:10.1111/acel.14272.